This treatment demonstrated lasting responses, addressing a significant unaccomplished demand for metastatic melanoma patients with restricted treatment options after acquiring resistance to the approved therapies, including the ones refractory to anti-PD-1 or PD-L1 therapy [15]. This evidence concerns the gene CD274 and metastatic melanoma.